ACTG A5257

---

* Opening Soon

Study Drugs

Arm A: Atazanavir + Ritonavir + Truvada

Arm B: Raltegravir +Truvada

Arm C: Darunavir + Ritonavir + Truvada

Randomization 1:1:1

Duration: 96 - 192 weeks

Eligibility Criteria

Treatment- naive, no known resistance to NRTI or PI

HIV-1 RNA >1000 copies/mL

 

Substudy A5260S

Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation with Emtricitabine/Tenofovir Disoproxial Fumarate (FTC/TDF) plus Atatzanavir/Ritonavir (ART/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Substudy of A5257

 

 

 

Contact

Graham Ray, RN, MSN (303) 724-0712

Beverly Putnam, RN, ANP (303) 724-0762
Cathi Basler, RN, ANP (303) 724-0708
Jim Scott, RN (303) 724-0801

---

 

BACK

 

Return to HOME